Drug intelligence / Profile preview

DWJ1558

Development stage: Phase 1
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DWJ1558 is a small molecule drug developed by Daewoong Pharmaceutical. It is currently in Phase 1 clinical trials, with studies focused on evaluating its pharmacokinetics and safety in healthy adult volunteers. The specific mechanism of action, molecular target(s), and therapeutic indications have not been publicly disclosed as of June 2025. The available clinical trial data centers on bioequivalence and safety assessments rather than efficacy for a particular disease[1][2][3].

Beyond the preview

Go deeper on DWJ1558.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWJ1558.

Explore the full profile